Schools without stock epinephrine were over 4 times as likely to lack a device in an allergic emergency, a survey of 349 school nurses found.
|Articles|October 1, 2012
A girl with abnormal movements and emotional lability puzzles doctors
While on the inpatient pediatric service, you receive a call from the emergency department (ED) about a 6-year-old girl who has abnormal movements and emotional lability. When meeting the child and her mother, you discover that the illness began about a week before presentation, when the child was sent home from school because of headache and vomiting.
Advertisement
Advertisement
Related to this article
In a matched cohort of children aged 6 and younger with EoE, dupilumab was linked to less incident asthma than swallowed budesonide (10.5% vs 16.2%).
Non-English-speaking families were far less likely to introduce peanut by 6 months (OR, 0.21) in a 3,170-child study presented at ACAAI 2026.
In an ACAAI 2026 survey, 85% of clinicians knew food allergy panels often yield false positives, yet many ordered them for unvalidated uses.
Full OptIMMize-1 results show high skin clearance rates with risankizumab in children and teens with psoriasis, sustained through 52 weeks.
Classroom engagement scores in digital gradebooks predicted substance use by eighth grade better than GPA (cross-validated AUC, 0.79 vs 0.63).
Children living more than 60 miles from their surgical hospital had higher complication odds and longer stays after common procedures.
Emily Becker, MD, discusses the role of AhR agonists, skin barrier function, and steroid-free treatment options for pediatric atopic dermatitis.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
How pediatricians can reframe vaccine conversations
2
Risankizumab shows 52-week efficacy in pediatric psoriasis trial
3
Language barriers linked to lower early peanut introduction rates
4
FDA investigates malignancy risk with SMA gene therapy Zolgensma
5